Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1985 2
1986 1
1987 6
1988 3
1989 9
1990 7
1991 4
1992 3
1993 1
1994 1
1995 4
1996 9
1997 2
1998 2
1999 6
2000 3
2001 2
2002 4
2003 5
2004 7
2005 9
2006 11
2007 11
2008 19
2009 26
2010 29
2011 35
2012 38
2013 54
2014 76
2015 83
2016 98
2017 106
2018 125
2019 127
2020 149
2021 150
2022 189
2023 162
2024 180
2025 241
2026 86

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,884 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.
Loibl S, Park YH, Shao Z, Huang CS, Barrios C, Abraham J, Prat A, Niikura N, Im SA, Li W, Li H, Wang Y, Yao H, Kim SB, Geng CZ, Rodriguez Pantigoso W, Ramírez Godinez FJ, Song C, Ching Chang Y, Antoniazzi A, Chen SC, Li Z, Nowecki Z, Lim J, Mathias E, Sato Y, Lu W, Abdel-Monem H, Untch M, Geyer CE Jr; DESTINY-Breast05 Trial Investigators. Loibl S, et al. Among authors: geng cz. N Engl J Med. 2026 Feb 26;394(9):845-857. doi: 10.1056/NEJMoa2514661. Epub 2025 Dec 10. N Engl J Med. 2026. PMID: 41370739
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.
Ma F, Yan M, Li W, Ouyang Q, Tong Z, Teng Y, Wang Y, Wang S, Geng C, Luo T, Zhong J, Zhang Q, Liu Q, Zeng X, Sun T, Mo Q, Liu H, Cheng Y, Cheng J, Wang X, Nie J, Yang J, Wu X, Wang X, Li H, Ye C, Dong F, Wu S, Zhu X, Xu B; PHILA Investigators. Ma F, et al. Among authors: geng c. BMJ. 2023 Oct 31;383:e076065. doi: 10.1136/bmj-2023-076065. BMJ. 2023. PMID: 37907210 Free PMC article. Clinical Trial.
Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024.
Li J, Hao C, Wang K, Zhang J, Chen J, Liu Y, Nie J, Yan M, Liu Q, Geng C, Wang X, Wang H, Wang S, Wu J, Yin Y, Song E, Jiang Z. Li J, et al. Among authors: geng c. Transl Breast Cancer Res. 2024 Jul 25;5:18. doi: 10.21037/tbcr-24-31. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39184927 Free PMC article. Review.
GameBus on FHIR.
Geng C, Khanshan A, van Gorp P. Geng C, et al. Stud Health Technol Inform. 2024 Aug 22;316:1312-1313. doi: 10.3233/SHTI240653. Stud Health Technol Inform. 2024. PMID: 39176622
1,884 results